Is Thrombocytopenia an Early Prognostic Marker in Septic Shock?

Critical Care Medicine

Volumn 44, Issue 4, 2016, Pages 764-772

  Thiery Antier, Nadiejda ^a   Binquet, Christine ^b   Vinault, Sandrine ^b   Meziani, Ferhat ^c,d,e   Boisramé Helms, Julie ^c,d,e   Quenot, Jean Pierre ^f,g  

^a Centre Hospitalier Chalon sur Saone   (France)

^b INSERM   (France)

^c HÔPITAL CIVIL   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

Author keywords

intensive care; prognosis; septic shock; thrombocytopenia

Indexed keywords

ADULT; AGED; ARTICLE; BACTEREMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SEPTIC SHOCK; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; CLINICAL TRIAL; COMPLICATION; FRANCE; HOSPITAL MORTALITY; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; FEMALE; FRANCE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; THROMBOCYTOPENIA;

EID: 84950125868     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001520     Document Type: Article

References (63)

1. Crowther MA, Cook DJ, Meade MO, Thrombocytopenia in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. J Crit Care 2005 20 348 353
2. Hui P, Cook DJ, Lim W, The frequency and clinical significance of thrombocytopenia complicating critical illness: A systematic review. Chest 2011 139 271 278
3. Baughman RP, Lower EE, Flessa HC, Thrombocytopenia in the intensive care unit. Chest 1993 104 1243 1247
4. Stéphan F, Hollande J, Richard O, Thrombocytopenia in a surgical ICU. Chest 1999 115 1363 1370
5. Vanderschueren S, De Weerdt A, Malbrain M, Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000 28 1871 1876
6. Lim SY, Jeon EJ, Kim HJ, The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: A prospective cohort study in a Korean hospital. J Korean Med Sci 2012 27 1418 1423
7. Williamson DR, Albert M, Heels-Ansdell D, PROTECT Collaborators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors, and outcomes. Chest 2013 144 1207 1215
8. Akca S, Haji-Michael P, de Mendonça A, Time course of platelet counts in critically ill patients. Crit Care Med 2002 30 753 756
9. Moreau D, Timsit JF, Vesin A, Platelet count decline: An early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007 131 1735 1741
10. Levy MM, Fink MP, Marshall JC, SCCM/ESICM/ACCP/ATS/SIS 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003 31 1250 1256
11. Angus DC, Linde-Zwirble WT, Lidicker J, Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 1303 1310
12. Annane D, Aegerter P, Jars-Guincestre MC, CUB-Réa Network Current epidemiology of septic shock: The CUB-Réa Network. Am J Respir Crit Care Med 2003 168 165 172
13. Kaukonen KM, Bailey M, Suzuki S, Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014 311 1308 1316
14. Boisramé-Helms J, Kremer H, Schini-Kerth V, Endothelial dysfunction in sepsis. Curr Vasc Pharmacol 2013 11 150 160
15. Delabranche X, Boisramé-Helms J, Asfar P, Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensive Care Med 2013 39 1695 1703
16. Meziani F, Delabranche X, Asfar P, Bench-to-bedside review: Circulating microparticles-A new player in sepsis? Crit Care 2010 14 236
17. Garraud O, Hamzeh-Cognasse H, Pozzetto B, Bench-to-bedside review: Platelets and active immune functions-New clues for immunopathology? Crit Care 2013 17 236
18. Opal S, Thijs L, Cavaillon JM, Roundtable I: Relationships between coagulation and inflammatory processes. Crit Care Med 2000 28 S81 S82
19. Gando S, Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010 38 S35 S42
20. Vandijck DM, Blot SI, De Waele JJ, Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung 2010 39 21 26
21. Stephan F, Montblanc Jd, Cheffi A, Thrombocytopenia in critically ill surgical patients: A case-control study evaluating attributable mortality and transfusion requirements. Crit Care 1999 3 151 158
22. Strauss R, Wehler M, Mehler K, Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002 30 1765 1771
23. Thiolliere F, Serre-Sapin AF, Reignier J, Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: Results of a prospective multicenter study. Intensive Care Med 2013 39 1460 1468
24. Moreno R, Vincent JL, Matos R, The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999 25 686 696
25. Moreno RP, Metnitz PG, Almeida E, SAPS 3 Investigators SAPS 3-From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005 31 1345 1355
26. Williamson DR, Lesur O, Tétrault JP, Thrombocytopenia in the critically ill: Prevalence, incidence, risk factors, and clinical outcomes. Can J Anaesth 2013 60 641 651
27. Brun-Buisson C, Meshaka P, Pinton P, EPISEPSIS Study Group EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004 30 580 588
28. Vincent JL, Sakr Y, Sprung CL, Sepsis Occurrence in Acutely Ill Patients Investigators Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006 34 344 353
29. van den Boogaard FE, Schouten M, de Stoppelaar SF, Thrombocytopenia impairs host defense during murine Streptococcus pneumoniae pneumonia. Crit Care Med 2015 43 e75 e83
30. Levy MM, Macias WL, Vincent JL, Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005 33 2194 2201
31. Pavon A, Binquet C, Kara F, EPIdemiology of Septic Shock (EPISS) Study Group Profile of the risk of death after septic shock in the present era: An epidemiologic study. Crit Care Med 2013 41 2600 2609
32. Quenot JP, Binquet C, Kara F, The epidemiology of septic shock in French intensive care units: The prospective multicenter cohort EPISS study. Crit Care 2013 17 R65
33. Ranieri VM, Thompson BT, Barie PS, PROWESS-SHOCK Study Group Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012 366 2055 2064
34. Le Gall JR, Lemeshow S, Saulnier F, A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993 270 2957 2963
35. Vincent JL, Moreno R, Takala J, The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996 22 707 710
36. Knaus WA, Zimmerman JE, Wagner DP, APACHE-acute physiology and chronic health evaluation: A physiologically based classification system. Crit Care Med 1981 9 591 597
37. Cox D., Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972 34 187 220
38. Shalansky SJ, Verma AK, Levine M, Risk markers for thrombocytopenia in critically ill patients: A prospective analysis. Pharmacotherapy 2002 22 803 813
39. Yaguchi A, Lobo FL, Vincent JL, Platelet function in sepsis. J Thromb Haemost 2004 2 2096 2102
40. Hunt BJ, Bleeding and coagulopathies in critical care. N Engl J Med 2014 370 847 859
41. Rice TW, Wheeler AP, Coagulopathy in critically ill patients: Part 1: Platelet disorders. Chest 2009 136 1622 1630
42. Weyrich AS, Zimmerman GA, Platelets: Signaling cells in the immune continuum. Trends Immunol 2004 25 489 495
43. Yeaman MR, The role of platelets in antimicrobial host defense. Clin Infect Dis 1997 25 951 968; quiz 969
44. Morrell CN, Aggrey AA, Chapman LM, Emerging roles for platelets as immune and inflammatory cells. Blood 2014 123 2759 2767
45. Gawaz M, Dickfeld T, Bogner C, Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997 23 379 385
46. Semple JW, Freedman J, Platelets and innate immunity. Cell Mol Life Sci 2010 67 499 511
47. Levi M, van der Poll T, Inflammation and coagulation. Crit Care Med 2010 38 S26 S34
48. Delabranche X, Berger A, Boisramé-Helms J, Microparticles and infectious diseases. Med Mal Infect 2012 42 335 343
49. Levi M, The coagulant response in sepsis and inflammation. Hamostaseologie 2010 30 10 12, 14-16
50. Ostrowski SR, Johansson PI, Rethinking platelet function: Thrombocytopenia induced immunodeficiency in critical illness. Med Hypotheses 2011 77 798 802
51. Yeaman MR, Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010 67 525 544
52. Vincent JL, Yagushi A, Pradier O, Platelet function in sepsis. Crit Care Med 2002 30 S313 S317
53. de Stoppelaar SF, van 't Veer C, Claushuis TA, Thrombocytopenia impairs host defense in Gram-negative pneumonia-derived sepsis in mice. Blood 2014 124 3781 3790
54. Levi M, Recombinant soluble thrombomodulin: Coagulation takes another chance to reduce sepsis mortality. J Thromb Haemost 2015 13 505 507
55. Yamakawa K, Aihara M, Ogura H, Recombinant human soluble thrombomodulin in severe sepsis: A systematic review and meta-analysis. J Thromb Haemost 2015 13 508 519
56. Marshall JC, Why have clinical trials in sepsis failed? Trends Mol Med 2014 20 195 203
57. Abraham E, Reinhart K, Opal S, OPTIMIST Trial Study Group Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003 290 238 247
58. Warren BL, Eid A, Singer P, KyberSept Trial Study Group Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001 286 1869 1878
59. Bernard GR, Vincent JL, Laterre PF, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 699 709
60. Kienast J, Juers M, Wiedermann CJ, KyberSept Investigators Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 4 90 97
61. Brown RE, Rimsza LM, Pastos K, Effects of sepsis on neonatal thrombopoiesis. Pediatr Res 2008 64 399 404
62. De Blasi RA, Cardelli P, Costante A, Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med 2013 39 636 643
63. Hong KH, Kim HK, Kim JE, Prognostic value of immature platelet fraction and plasma thrombopoietin in disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2009 20 409 414